LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on PYXS stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky has given his Buy rating due to a combination of factors related to Pyxis Oncology’s promising developments. The company has reported encouraging efficacy signals from its Phase 1 dose escalation study of micvotabart pelido (MICVO) in patients with head and neck squamous cell carcinoma (HNSCC). This positive data has led Pyxis to focus its development efforts on this patient population, with plans to release preliminary data from three separate cohorts by the end of 2025.
Moreover, Pyxis Oncology is pursuing a comprehensive clinical program that includes both monotherapy and combination therapy approaches, such as combining MICVO with Keytruda. This strategy highlights the potential of their first-in-concept antibody-drug conjugate (ADC) to improve treatment outcomes across multiple lines of therapy. Additionally, the company has been active in presenting translational data at major medical conferences, further supporting the potential of MICVO’s mechanism of action.
In another report released yesterday, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $9.00 price target.